Back
Orgenesis 10K Form
Sell
31
ORGS
Orgenesis
Last Price:
0.51
Seasonality Move:
-11.46%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-06 | 10Q | ORGS/Orgenesis Quarterly |
| 2020-05-08 | 10Q | ORGS/Orgenesis Quarterly |
| 2020-03-09 | 10K | ORGS/Orgenesis Annual |
| 2019-11-07 | 10Q | ORGS/Orgenesis Quarterly |
| 2019-08-08 | 10Q | ORGS/Orgenesis Quarterly |
| 2019-05-08 | 10Q | ORGS/Orgenesis Quarterly |
Receive ORGS News And Ratings
See the #1 stock for the next 7 days that we like better than ORGS
ORGS Financial Statistics
Sales & Book Value
| Annual Sales: | $530K |
|---|---|
| Cash Flow: | $-502K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.66 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -1.96000 |
|---|---|
| Net Income (TTM): | $-55.36M |
| Gross Margin: | $-5.73M |
| Return on Equity: | -206.63% |
| Return on Assets: | -92.64% |
Orgenesis Earnings Forecast
Key Orgenesis Financial Ratios
- The Gross Profit Margin over the past 16 years for ORGS is -1,080.19%.
- The Selling, General & Administrative Expenses for ORGS have been equal to 6,620.38% of Gross Profit Margin.
- The Research & Development expenses have been 2,004.34% of Revenue.
- The Interest Expense is -3.91% of Operating Income.
- The Net Earning history of ORGS is -10,445.47% of Total Revenues.
- Per Share Earnings over the last 16 years have been positive in 4 years.
Orgenesis Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Current Symbol: | ORGS |
| CUSIP: | 68619K |
| Website: | orgenesis.com |
Debt
| Debt-to-Equity Ratio: | -1.06 |
|---|---|
| Current Ratio: | 0.25 |
| Quick Ratio: | 0.21 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |